Cancer Communications

Papers
(The H4-Index of Cancer Communications is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020513
Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020475
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021378
Ferroptosis in cancer and cancer immunotherapy276
Non‐small cell lung cancer in China213
EMT‐associated microRNAs and their roles in cancer stemness and drug resistance187
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma177
Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review142
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy136
A global assessment of recent trends in gastrointestinal cancer and lifestyle‐associated risk factors128
Breast cancer: an up‐to‐date review and future perspectives126
The role of the HIF‐1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer126
New insights into the interplay between long non‐coding RNAs and RNA‐binding proteins in cancer121
Advancing to the era of cancer immunotherapy99
Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine99
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase 97
Aberrant translation regulated by METTL1/WDR4‐mediated tRNA N7‐methylguanosine modification drives head and neck squamous cell carcinoma progression92
Essential roles of exosome and circRNA_101093 on ferroptosis desensitization in lung adenocarcinoma89
Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities86
Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art81
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives79
Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy75
Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma74
The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential72
Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy67
New insights into molecules and pathways of cancer metabolism and therapeutic implications66
An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment65
Multifunctional inorganic nanomaterials for cancer photoimmunotherapy65
N‐acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4‐acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA62
The Fibrillin‐1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells59
Tumor microenvironment signaling and therapeutics in cancer progression57
Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa‐miR‐6887‐3p57
The theory of tumor ecosystem56
Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells56
Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities53
Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?52
HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program50
S100A8 promotes epithelial‐mesenchymal transition and metastasis under TGF‐β/USF2 axis in colorectal cancer49
Trends in cancer mortality in China from 2004 to 2018: A nationwide longitudinal study49
Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 149
Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib45
KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer44
Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates44
0.079080820083618